On Wednesday, Amgen stock earned an upgrade to its Relative Strength (RS) Rating, from 68 to 80.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating in the early stages of their moves.
Looking For Winning Stocks? Try This Simple Routine
Is Amgen Stock A Buy?
Amgen stock is building a cup without handle with a 296.67 entry. See if it can clear the breakout price in heavy trade. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Earnings grew 8% last quarter, up from -6% in the prior report. Revenue also increased, from -2% to 6%.
Amgen stock holds the No. 12 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals and Kiniksa Pharmaceuticals are also among the group's highest-rated stocks. For industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
